NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Period	Debt/Equity
2020-12-31	-1.07
2021-12-31	0.57
2022-12-31	2.48
2023-12-31	-1.62
2024-12-31	-1.16

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$2.26	+1.26%	0.63M
3
4
5

NRX Pharmaceuticals Inc. (NRXP) Debt to Equity Ratio

Debt to Equity Ratio Data

Get NRX Pharmaceuticals Inc. Data in Excel

More NRXP Financial Data